Annual SGA
$236.67 M
-$13.08 M-5.24%
December 31, 2024
Summary
- As of February 26, 2025, RPRX annual SGA is $236.67 million, with the most recent change of -$13.08 million (-5.24%) on December 31, 2024.
- During the last 3 years, RPRX annual SGA has risen by +$53.84 million (+29.45%).
- RPRX annual SGA is now -5.24% below its all-time high of $249.75 million, reached on December 31, 2023.
Performance
RPRX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$67.59 M
+$10.87 M+19.17%
December 31, 2024
Summary
- As of February 26, 2025, RPRX quarterly SGA is $67.59 million, with the most recent change of +$10.87 million (+19.17%) on December 31, 2024.
- Over the past year, RPRX quarterly SGA has increased by +$8.41 million (+14.20%).
- RPRX quarterly SGA is now -21.13% below its all-time high of $85.69 million, reached on March 31, 2023.
Performance
RPRX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
$10.42 B
+$328.07 M+3.25%
December 31, 2024
Summary
- As of February 26, 2025, RPRX TTM SGA is $10.42 billion, with the most recent change of +$328.07 million (+3.25%) on December 31, 2024.
- Over the past year, RPRX TTM SGA has increased by +$10.17 billion (+4070.62%).
- RPRX TTM SGA is now at all-time high.
Performance
RPRX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RPRX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.2% | +14.2% | +4070.6% |
| 3 y3 years | +29.4% | +14.2% | +4070.6% |
| 5 y5 years | +128.8% | +14.2% | +4070.6% |
RPRX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.2% | +29.4% | -21.1% | +46.4% | at high | +21.6% |
| 5 y | 5-year | -5.2% | +128.8% | -21.1% | +193.1% | at high | +268.7% |
| alltime | all time | -5.2% | +282.3% | -21.1% | +193.1% | at high | +268.7% |
Royalty Pharma Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $236.67 M(-5.2%) | $67.59 M(+19.2%) | $236.67 M(+3.7%) |
| Sep 2024 | - | $56.72 M(+3.7%) | $228.26 M(-0.2%) |
| Jun 2024 | - | $54.71 M(-5.1%) | $228.78 M(+3.2%) |
| Mar 2024 | - | $57.65 M(-2.6%) | $221.71 M(-11.2%) |
| Dec 2023 | $249.75 M(+9.9%) | $59.19 M(+3.4%) | $249.75 M(-5.3%) |
| Sep 2023 | - | $57.23 M(+20.2%) | $263.79 M(+2.5%) |
| Jun 2023 | - | $47.63 M(-44.4%) | $257.25 M(-1.6%) |
| Mar 2023 | - | $85.69 M(+17.0%) | $261.46 M(+15.0%) |
| Dec 2022 | $227.30 M(+24.3%) | $73.23 M(+44.5%) | $227.30 M(+13.5%) |
| Sep 2022 | - | $50.69 M(-2.2%) | $200.24 M(+1.1%) |
| Jun 2022 | - | $51.84 M(+0.6%) | $198.13 M(+3.6%) |
| Mar 2022 | - | $51.54 M(+11.7%) | $191.21 M(+4.6%) |
| Dec 2021 | $182.83 M | $46.16 M(-5.0%) | $182.83 M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $48.59 M(+8.2%) | $186.78 M(-1.1%) |
| Jun 2021 | - | $44.92 M(+4.1%) | $188.93 M(+1.1%) |
| Mar 2021 | - | $43.16 M(-13.9%) | $186.81 M(+2.8%) |
| Dec 2020 | $181.72 M(+75.7%) | $50.12 M(-1.2%) | $181.72 M(+17.5%) |
| Sep 2020 | - | $50.73 M(+18.5%) | $154.66 M(+19.4%) |
| Jun 2020 | - | $42.80 M(+12.4%) | $129.53 M(+10.6%) |
| Mar 2020 | - | $38.06 M(+65.1%) | $117.08 M(+13.2%) |
| Dec 2019 | $103.44 M(+67.1%) | $23.06 M(-9.9%) | $103.44 M(+28.7%) |
| Sep 2019 | - | $25.60 M(-15.6%) | $80.38 M(+46.7%) |
| Jun 2019 | - | $30.35 M(+24.2%) | $54.77 M(+124.2%) |
| Mar 2019 | - | $24.43 M | $24.43 M |
| Dec 2018 | $61.91 M(-41.8%) | - | - |
| Dec 2017 | $106.44 M | - | - |
FAQ
- What is Royalty Pharma annual SGA?
- What is the all time high annual SGA for Royalty Pharma?
- What is Royalty Pharma annual SGA year-on-year change?
- What is Royalty Pharma quarterly SGA?
- What is the all time high quarterly SGA for Royalty Pharma?
- What is Royalty Pharma quarterly SGA year-on-year change?
- What is Royalty Pharma TTM SGA?
- What is the all time high TTM SGA for Royalty Pharma?
- What is Royalty Pharma TTM SGA year-on-year change?
What is Royalty Pharma annual SGA?
The current annual SGA of RPRX is $236.67 M
What is the all time high annual SGA for Royalty Pharma?
Royalty Pharma all-time high annual SGA is $249.75 M
What is Royalty Pharma annual SGA year-on-year change?
Over the past year, RPRX annual SGA has changed by -$13.08 M (-5.24%)
What is Royalty Pharma quarterly SGA?
The current quarterly SGA of RPRX is $67.59 M
What is the all time high quarterly SGA for Royalty Pharma?
Royalty Pharma all-time high quarterly SGA is $85.69 M
What is Royalty Pharma quarterly SGA year-on-year change?
Over the past year, RPRX quarterly SGA has changed by +$8.41 M (+14.20%)
What is Royalty Pharma TTM SGA?
The current TTM SGA of RPRX is $10.42 B
What is the all time high TTM SGA for Royalty Pharma?
Royalty Pharma all-time high TTM SGA is $10.42 B
What is Royalty Pharma TTM SGA year-on-year change?
Over the past year, RPRX TTM SGA has changed by +$10.17 B (+4070.62%)